Publications by authors named "Hans Vermeij"
Article Synopsis
- Leukoreduction (LR) is a standard practice to reduce risks associated with platelet transfusions, but it doesn't prevent transfusion-associated graft-versus-host disease (TA-GVHD), which can be mitigated by Amotosalen-ultraviolet A pathogen reduction (A-PR).
- A study comparing A-PR platelet concentrates without LR to conventional controls showed similar efficacy in achieving platelet increments and a lower incidence of acute transfusion reactions, although not statistically significant.
- The results suggest that using A-PR for platelet support in hematopoietic stem cell transplant recipients is a viable option, with no significant differences in major safety concerns like TA-GVHD or infection rates after 100 days.
Background: A photochemical treatment (PCT) process using the psoralen compound amotosalen HCL (S59) and long wavelength UVA light was developed for inactivation of infectious pathogens and WBCs. In this study the effect of PCT on functional characteristics of the platelets was evaluated in vitro.
Study Design And Methods: Platelet concentrates were treated photochemically using the experimental clinical processing system T-bag S59 Reduction Device (SRD) (n = 4) or the commercially available integral processing system Wafer SRD (n = 4) and compared with control platelet concentrates in plasma/PAS III alone (n = 4).
A nucleic acid-targeted photochemical treatment (PCT) using amotosalen HCl (S-59) and ultraviolet A (UVA) light was developed to inactivate viruses, bacteria, protozoa, and leukocytes in platelet components. We conducted a controlled, randomized, double-blinded trial in thrombocytopenic patients requiring repeated platelet transfusions for up to 56 days of support to evaluate the therapeutic efficacy and safety of platelet components prepared with the buffy coat method using this pathogen inactivation process. A total of 103 patients received one or more transfusions of either PCT test (311 transfusions) or conventional reference (256 transfusions) pooled, leukoreduced platelet components stored for up to 5 days before transfusion.
View Article and Find Full Text PDF